294.28
price up icon7.13%   19.58
after-market Handel nachbörslich: 294.28
loading
Schlusskurs vom Vortag:
$274.70
Offen:
$284.65
24-Stunden-Volumen:
2.43M
Relative Volume:
4.25
Marktkapitalisierung:
$13.27B
Einnahmen:
$2.99B
Nettoeinkommen (Verlust:
$1.21B
KGV:
11.74
EPS:
25.06
Netto-Cashflow:
$1.13B
1W Leistung:
-3.36%
1M Leistung:
+1.16%
6M Leistung:
-16.20%
1J Leistung:
-10.22%
1-Tages-Spanne:
Value
$283.01
$296.60
1-Wochen-Bereich:
Value
$272.12
$306.24
52-Wochen-Spanne:
Value
$266.98
$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Name
Firmenname
United Therapeutics Corp
Name
Telefon
(301) 608-9292
Name
Adresse
1000 SPRING ST, SILVER SPRING, MD
Name
Mitarbeiter
1,305
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-30
Name
Neueste SEC-Einreichungen
Name
UTHR's Discussions on Twitter

Vergleichen Sie UTHR mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
294.28 12.42B 2.99B 1.21B 1.13B 25.06
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
147.38 64.91B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.16 43.33B 29.98B 958.27M 5.31B 0.2964
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.66 42.36B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
15.38 17.72B 16.54B -1.64B 749.00M -1.45

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-02 Eingeleitet Cantor Fitzgerald Overweight
2025-04-25 Herabstufung Wells Fargo Overweight → Equal Weight
2025-04-21 Hochstufung BofA Securities Underperform → Neutral
2024-07-11 Herabstufung Morgan Stanley Overweight → Equal-Weight
2024-02-12 Hochstufung Goldman Sell → Neutral
2024-02-05 Eingeleitet Leerink Partners Outperform
2023-12-08 Eingeleitet Wells Fargo Overweight
2022-12-06 Eingeleitet UBS Buy
2022-12-05 Eingeleitet Goldman Sell
2022-10-11 Eingeleitet Morgan Stanley Overweight
2022-09-20 Bestätigt BofA Securities Underperform
2022-09-19 Fortgesetzt Wedbush Outperform
2022-02-11 Eingeleitet BTIG Research Neutral
2021-07-14 Hochstufung Argus Hold → Buy
2021-04-26 Fortgesetzt Credit Suisse Outperform
2021-02-01 Hochstufung H.C. Wainwright Neutral → Buy
2020-09-14 Fortgesetzt JP Morgan Overweight
2020-06-25 Bestätigt H.C. Wainwright Neutral
2020-03-10 Hochstufung Jefferies Hold → Buy
2020-02-27 Hochstufung Cowen Market Perform → Outperform
2020-01-31 Hochstufung JP Morgan Neutral → Overweight
2019-12-03 Eingeleitet BofA/Merrill Underperform
2019-08-01 Hochstufung Jefferies Underperform → Hold
2019-08-01 Hochstufung Ladenburg Thalmann Neutral → Buy
2019-07-01 Hochstufung Credit Suisse Neutral → Outperform
2019-05-17 Hochstufung UBS Sell → Neutral
2019-05-09 Hochstufung Credit Suisse Underperform → Neutral
2018-10-12 Hochstufung Standpoint Research Hold → Buy
2018-08-08 Herabstufung Credit Suisse Neutral → Underperform
2018-04-03 Hochstufung Credit Suisse Underperform → Neutral
2018-02-22 Bestätigt Barclays Underweight
2018-01-18 Fortgesetzt Credit Suisse Underperform
2017-12-27 Bestätigt Wedbush Outperform
2017-04-27 Bestätigt Wedbush Outperform
2017-03-30 Eingeleitet UBS Sell
2017-03-16 Eingeleitet Credit Suisse Underperform
Alle ansehen

United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten

pulisher
Aug 01, 2025

United Therapeutics Announces $1B Accelerated Share Repurchase Program. - AInvest

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics’ PAH Study Update: Implications for Investors - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment - TipRanks

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics (UTHR) Launches $1B Stock Buyback Program - GuruFocus

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Launches $1 Bln Stock Buyback - Nasdaq

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics stock jumps on $1 billion share repurchase plan - Investing.com

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Unveils Massive $1B Stock Buyback Plan in Strategic Financial Move - Stock Titan

Aug 01, 2025
pulisher
Aug 01, 2025

Pulmonary Arterial Hypertension Drug Market to See Booming - openPR.com

Aug 01, 2025
pulisher
Aug 01, 2025

What is the dividend policy of United Therapeutics Corporation stockFree Stock Alerts For Every Investor - jammulinksnews.com

Aug 01, 2025
pulisher
Aug 01, 2025

United Therapeutics Reports Record Q2 2025 Financial Results - The Globe and Mail

Aug 01, 2025
pulisher
Jul 31, 2025

BTIG Lowers Liquidia (LQDA) PT to $40, Potential for Yutrepia Launch Remains a Focus - Insider Monkey

Jul 31, 2025
pulisher
Jul 31, 2025

United Therapeutics Reports Record Revenue and Growth - TipRanks

Jul 31, 2025
pulisher
Jul 31, 2025

H.C. Wainwright lowers United Therapeutics stock price target on Tyvaso competition concerns - Investing.com Nigeria

Jul 31, 2025
pulisher
Jul 31, 2025

United Therapeutics Corp (UTHR) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada

Jul 31, 2025
pulisher
Jul 31, 2025

United Therapeutics: Q2 Earnings Snapshot - Greenwich Time

Jul 31, 2025
pulisher
Jul 31, 2025

Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight - GuruFocus

Jul 31, 2025
pulisher
Jul 30, 2025

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for IPF Treatment - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Stock Slides On Q2 Earnings: The Details - 富途牛牛

Jul 30, 2025
pulisher
Jul 30, 2025

Earnings call transcript: United Therapeutics Q2 2025 misses EPS, stock drops - Investing.com

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks

Jul 30, 2025
pulisher
Jul 30, 2025

Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics - Nasdaq

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Q2 2025 slides: Revenue up 12% as Tyvaso drives growth - Investing.com India

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Logs Growth And Launches Big Buyback - Finimize

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics misses Q2 earnings expectations By Investing.com - Investing.com Canada

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics misses Q2 earnings expectations - Investing.com

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results - TradingView

Jul 30, 2025
pulisher
Jul 30, 2025

UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics earnings missed by $0.94, revenue fell short of estimates - Investing.com

Jul 30, 2025
pulisher
Jul 30, 2025

United Therapeutics Delivers Triple Win: Record $799M Revenue, $1B Buyback, and Major Pipeline Progress - Stock Titan

Jul 30, 2025
pulisher
Jul 29, 2025

United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial - MSN

Jul 29, 2025
pulisher
Jul 29, 2025

United Therapeutics’ Promising IPF Treatment Study: A Market Game-Changer? - The Globe and Mail

Jul 29, 2025
pulisher
Jul 29, 2025

Preview: United Therapeutics's Earnings - 富途牛牛

Jul 29, 2025
pulisher
Jul 29, 2025

Bleecker Street Research short United Therapeutics, long Liquidia - TipRanks

Jul 29, 2025
pulisher
Jul 29, 2025

Published on: 2025-07-29 12:41:34 - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

United Therapeutics Earnings Announcement and Market OutlookNews and Statistics - IndexBox

Jul 29, 2025
pulisher
Jul 29, 2025

Is There Enough Volume to Lift United Therapeutics CorporationTriple Return Setup With Risk Control Explained - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) - MSN

Jul 29, 2025
pulisher
Jul 29, 2025

Why United Therapeutics Corporation stock attracts strong analyst attentionWeekly Top Gainers Forecast Watchlist Released - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

What institutions are buying United Therapeutics Corporation stock nowEarnings Play Trade Plan With Alerts Shared - metal.it

Jul 29, 2025
pulisher
Jul 28, 2025

What To Expect From United Therapeutics’s (UTHR) Q2 Earnings - Yahoo.co

Jul 28, 2025
pulisher
Jul 28, 2025

ROSEN, A LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Jul 28, 2025
pulisher
Jul 28, 2025

How many analysts rate United Therapeutics Corporation as a “Buy”Entry Signal Forecasts With Low Risk - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is United Therapeutics Corporation stock compared to the marketStay informed with daily expert analysis - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about United Therapeutics CorporationRapid-fire capital growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT - Insider Monkey

Jul 28, 2025
pulisher
Jul 27, 2025

When is United Therapeutics Corporation stock expected to show significant growthHigh-performance stocks for savvy investors - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

Is United Therapeutics Corporation stock overvalued or undervaluedHigh-yield portfolio picks - jammulinksnews.com

Jul 27, 2025

Finanzdaten der United Therapeutics Corp-Aktie (UTHR)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$128.91
price up icon 0.53%
drug_manufacturers_specialty_generic RDY
$13.94
price down icon 1.97%
$8.81
price up icon 0.80%
$15.38
price down icon 0.45%
$13.79
price up icon 0.80%
Kapitalisierung:     |  Volumen (24h):